Literature DB >> 34647145

Prediction of insufficient hepatic enhancement during the Hepatobiliary phase of Gd-EOB DTPA-enhanced MRI using machine learning classifier and feature selection algorithms.

Jieun Byun1,2, Seongkeun Park3, Ji Su Ko4, Ji Young Woo4.   

Abstract

PURPOSE: The purpose of this study was to reveal the usefulness of machine learning classifier and feature selection algorithms for prediction of insufficient hepatic enhancement in the HBP.
METHODS: We retrospectively assessed 214 patients with chronic liver disease or liver cirrhosis who underwent MRI enhanced with Gd-EOB-DTPA. Various liver function tests, Child-Pugh score (CPS) and Model for End-stage Liver Disease Sodium (MELD-Na) score were collected as candidate predictors for insufficient hepatic enhancement. Insufficient hepatic enhancement was assessed using liver-to-portal vein signal intensity ratio and 5-level visual grading. The clinico-laboratory findings were compared using Student's t-test and Mann-Whitney U test. Relationships between the laboratory tests and insufficient hepatic enhancement were assessed using Pearson's and Spearman's rank correlation coefficient. Feature importance was assessed by Random UnderSampling boosting algorithms. The predictive models were constructed using decision tree(DT), k-nearest neighbor(KNN), random forest(RF), and support-vector machine(SVM) classifier algorithms. The performances of the prediction models were analyzed by calculating the area under the receiver operating characteristic curve(AUC).
RESULTS: Among four machine learning classifier algorithms using various feature combinations, SVM using total bilirubin(TB) and albumin(Alb) showed excellent predictive ability for insufficient hepatic enhancement(AUC = 0.93, [95% CI: 0.93-0.94]) and higher AUC value than conventional logistic regression(LR) model (AUC = 0.92, [95% CI; 0.92-0.93], predictive models using the MELD-Na (AUC = 0.90 [95% CI: 0.89-0.91]) and CPS (AUC = 0.89 [95% CI: 0.88-0.90]).
CONCLUSION: Machine learning-based classifier (i.e. SVM) and feature selection algorithms can be used to predict insufficient hepatic enhancement in the HBP before performing MRI.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Gadolinium ethoxybenzyl DTPA; Hepatobiliary images; Insufficient hepatic enhancement; Machine learning

Mesh:

Substances:

Year:  2021        PMID: 34647145     DOI: 10.1007/s00261-021-03308-0

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  26 in total

1.  Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation.

Authors:  Takahiro Tsuboyama; Hiromitsu Onishi; Tonsok Kim; Hirofumi Akita; Masatoshi Hori; Mitsuaki Tatsumi; Atsushi Nakamoto; Hiroaki Nagano; Nariaki Matsuura; Kenichi Wakasa; Kaname Tomoda
Journal:  Radiology       Date:  2010-06       Impact factor: 11.105

2.  Fate of hypointense lesions on Gd-EOB-DTPA-enhanced magnetic resonance imaging.

Authors:  Hiroyuki Akai; Izuru Matsuda; Shigeru Kiryu; Taku Tajima; Hidemasa Takao; Yasushi Watanabe; Hiroshi Imamura; Norihiro Kokudo; Masaaki Akahane; Kuni Ohtomo
Journal:  Eur J Radiol       Date:  2012-01-26       Impact factor: 3.528

3.  Impact of liver cirrhosis on liver enhancement at Gd-EOB-DTPA enhanced MRI at 3 Tesla.

Authors:  N Verloh; M Haimerl; J Rennert; R Müller-Wille; C Nießen; G Kirchner; M N Scherer; A G Schreyer; C Stroszczynski; C Fellner; P Wiggermann
Journal:  Eur J Radiol       Date:  2013-06-25       Impact factor: 3.528

4.  Development and validation of a predictor of insufficient enhancement during the hepatobiliary phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging.

Authors:  Enming Cui; Wansheng Long; Liangping Luo; Maoqing Hu; Liebin Huang; Xiangmeng Chen
Journal:  Acta Radiol       Date:  2017-01-16       Impact factor: 1.990

5.  Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging.

Authors:  Taku Tajima; Hidemasa Takao; Hiroyuki Akai; Shigeru Kiryu; Hiroshi Imamura; Yasushi Watanabe; Jyunichi Shibahara; Norihiro Kokudo; Masaaki Akahane; Kuni Ohtomo
Journal:  J Comput Assist Tomogr       Date:  2010 May-Jun       Impact factor: 1.826

6.  Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features.

Authors:  Azusa Kitao; Yoh Zen; Osamu Matsui; Toshifumi Gabata; Satoshi Kobayashi; Wataru Koda; Kazuto Kozaka; Norihide Yoneda; Tatsuya Yamashita; Shuichi Kaneko; Yasuni Nakanuma
Journal:  Radiology       Date:  2010-07-27       Impact factor: 11.105

7.  Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging.

Authors:  B Hamm; T Staks; A Mühler; M Bollow; M Taupitz; T Frenzel; K J Wolf; H J Weinmann; L Lange
Journal:  Radiology       Date:  1995-06       Impact factor: 11.105

8.  Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis.

Authors:  Ah Yeong Kim; Young Kon Kim; Min Woo Lee; Min Jung Park; Jiyoung Hwang; Mi Hee Lee; Jae Won Lee
Journal:  Acta Radiol       Date:  2012-07-30       Impact factor: 1.990

9.  Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement?

Authors:  Utaroh Motosugi; Tomoaki Ichikawa; Hironobu Sou; Katsuhiro Sano; Licht Tominaga; Takatoshi Kitamura; Tsutomu Araki
Journal:  J Magn Reson Imaging       Date:  2009-11       Impact factor: 4.813

10.  Dynamic and delayed contrast enhancement in upper abdominal MRI studies: comparison of gadoxetic acid and gadobutrol.

Authors:  Jan Zizka; Ludovít Klzo; Jirí Ferda; Milan Mrklovský; Josef Bukac
Journal:  Eur J Radiol       Date:  2007-03-23       Impact factor: 3.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.